Stefania Pezzana

Stefania Pezzana

Auto-generated profile, based on publicly available information

Stefania Pezzana

Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University Hospital Tübingen, Eberhard Karls University Tübingen; Tübingen, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in Immunology Letters
Verified
Journal Article
Open access
CVClaudia Vanetti
Claudia Vanetti
MBMartina Broggiato
Martina Broggiato
SPStefania Pezzana
Stefania Pezzana
mario clericimario clerici
mario clerici
CFClaudio Fenizia
Claudio Fenizia
Plastics are everywhere. It is widely recognized that they represent a global problem, the extent of which is yet to be defined. Humans are broadly exposed to plastics, whose effects and consequences are poorly characterized so far. The main route of exposure is via alimentary and respiratory intake. Plastics pollutions may come from both: water and food contamination itself, and their packaging. The smaller sizes (i.e. microplastics <150 µm - MPs) are considered to be the most pervasive of living organisms and, therefore, potentially the most harmful. As humans occupy one of the apex positions of the food chain, we are exposed to bioaccumulation and biomagnification effects of MPs. In fact, MPs are commonly found in human stools and blood. However, there are no data available yet on their ability to accumulate and to produce detrimental consequences on biological systems. Even though the effects of plastics pollution are poorly studied in mammals, including humans, they appear to have inflammatory effects, which is rather concerning as many etiologies of disease are based on a pro-inflammatory status.

27 June 2025 in Science Advances
Verified
Journal Article
Open access
SPStefania Pezzana
Stefania Pezzana
SBSimone Blaess
Simone Blaess
BTBjoern Traenkle
Bjoern Traenkle
ASAnna Schaefer
Anna Schaefer
LRLara Ruoff
Lara Ruoff
DSDominik Sonanini
Dominik Sonanini
CD4 + T cells are crucial in shaping response and resistance to immunotherapy. To enhance our understanding of their multifaceted functions, we developed copper-64–radiolabeled nanobodies targeting the human CD4 receptor ( 64 Cu-CD4-Nb1) for positron emission tomography (PET). In human CD4-receptor knock-in mice, 64 Cu-CD4-Nb1 specifically accumulated in different orthotopic tumors, correlating with histological CD4 + cell densities. Based on intratumoral CD4 + cell distribution patterns within the core and periphery, we distinguished responders to combined αPD-1/4-1BB antibodies early on-treatment. CD4-PET identified resistance to αPD-1 monotherapy, which was mitigated by adding regulatory T cell–depleting α4-1BB antibodies. Patients with early-stage non–small cell lung cancer who relapsed after neoadjuvant αPD-L1 therapy revealed low CD4 + T cell densities in the tumor core. In human and mouse tumor tissues, regulatory T cells correlated with CD4 + cell densities. Thus, visualizing the spatial distribution patterns of CD4 + cells by PET offers mechanistic insights into CD4-mediated therapy efficacy, with great potential for guiding combinatorial immunotherapies in patients with cancer.

7 August 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SLSixing Li
Sixing Li
MNMarie-Aline Neveu
Marie-Aline Neveu
LKLaura Kuebler
Laura Kuebler
SPStefania Pezzana
Stefania Pezzana
ABAinara Barco-Tejada
Ainara Barco-Tejada
André F. MartinsAndré F. Martins
André F. Martins
The limited efficacy of immune checkpoint inhibitor (ICI) therapy in triple-negative breast cancer (TNBC) highlights the need for combination strategies that enhance antitumor responses. Sorafenib, a multikinase inhibitor with anti-angiogenic and immunomodulatory activity, represents a rational partner for ICI-based combination therapy. However, therapeutic responses to such combinations are biologically complex and cannot be fully characterized by any single biomarker or imaging modality. Here, we evaluated ICI therapy combined with sorafenib in the aggressive and ICI-refractory orthotopic 4T1 TNBC model. Therapeutic responses were assessed using a unique longitudinal multimodal imaging framework integrating [⁸⁹Zr]Zr-DFO–anti-CD8 minibody and [¹⁸F]FDG PET, as well as perfluorocarbon (PFC)-based ¹⁹F MRI and hyperpolarized ¹³C MRS, together with ex vivo analyses. Only the ICI–sorafenib combination suppressed tumor growth, whereas both monotherapies showed limited antitumor activity. Multimodal imaging, together with complementary ex vivo analyses, uncovered coordinated tumor microenvironment (TME) remodeling, including vascular normalization, elevated CD8⁺ cell presence with modest enrichment in the tumor center, delayed increase in phagocyte-associated ¹⁹F MRI signal coupled with reduced CD206⁺ cell infiltration, and sustained metabolic activity. These findings support ICI–sorafenib combination therapy as a promising therapeutic strategy for TNBC. Therapeutic efficacy reflected coordinated vascular, immune, and metabolic remodeling. This multimodal imaging framework enables non-invasive longitudinal monitoring of these complementary TME changes, providing a comprehensive strategy for treatment assessment in immunotherapy-based combination therapies. One Sentence Summary: Longitudinal multimodal imaging identified a multidimensional TME response signature of effective ICI-sorafenib therapy in TNBC.